Magnesium for preventing preterm birth after threatened preterm labour

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Neonatal Research

Background:

• Threatened preterm labor often leads to interventions aimed at preventing birth before 37 weeks gestation.
• Magnesium sulfate is sometimes administered as maintenance therapy post-initial treatment for threatened preterm labor.
• The efficacy of continued magnesium therapy in preventing recurrent preterm contractions remains uncertain.

Purpose of the Study:

• To systematically review randomized controlled trials evaluating the effectiveness of magnesium maintenance therapy.
• To assess the impact of magnesium maintenance therapy on preventing preterm birth following an episode of threatened preterm labor.

Main Methods:

• Searched the Cochrane Pregnancy and Childbirth Group trials register for relevant studies.
• Included randomized controlled trials comparing magnesium therapy to alternative treatments or no treatment.
• Conducted independent quality assessment and data extraction by two reviewers.

Main Results:

• Only two trials met the inclusion criteria, both of which were of poor methodological quality.
• Neither included study provided long-term follow-up data for infants.
• Magnesium maintenance therapy did not demonstrate a reduction in preterm birth or perinatal mortality rates compared to control groups.

Conclusions:

• There is currently insufficient high-quality evidence to support the use of magnesium maintenance therapy.
• The effectiveness of magnesium therapy in preventing recurrent preterm labor and subsequent birth is not established.
• Further well-designed trials are needed to clarify the role of magnesium maintenance therapy in managing threatened preterm labor.